PH26712A - Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt - Google Patents
Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt Download PDFInfo
- Publication number
- PH26712A PH26712A PH37251A PH37251A PH26712A PH 26712 A PH26712 A PH 26712A PH 37251 A PH37251 A PH 37251A PH 37251 A PH37251 A PH 37251A PH 26712 A PH26712 A PH 26712A
- Authority
- PH
- Philippines
- Prior art keywords
- weight
- composition
- optionally
- cholinergic
- salt
- Prior art date
Links
- 239000003833 bile salt Substances 0.000 title description 6
- 239000000064 cholinergic agonist Substances 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003488 releasing hormone Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 26
- 102100022831 Somatoliberin Human genes 0.000 claims description 16
- 101710142969 Somatoliberin Proteins 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000001713 cholinergic effect Effects 0.000 claims description 9
- 229960002362 neostigmine Drugs 0.000 claims description 7
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims description 7
- 210000000941 bile Anatomy 0.000 claims description 6
- 208000037824 growth disorder Diseases 0.000 claims description 5
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 4
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 159000000011 group IA salts Chemical class 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- 241000270276 Natrix Species 0.000 claims 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 claims 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical group C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 claims 1
- 229960002329 methacholine Drugs 0.000 claims 1
- 229940100652 nasal gel Drugs 0.000 claims 1
- 229940100657 nasal ointment Drugs 0.000 claims 1
- 229960001697 physostigmine Drugs 0.000 claims 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- 229960001661 ursodiol Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 21
- 239000012153 distilled water Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000015107 ale Nutrition 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- -1 cresm Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003748 edrophonium Drugs 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960002931 methacholine chloride Drugs 0.000 description 1
- JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT21513/87A IT1222395B (it) | 1987-07-30 | 1987-07-30 | Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26712A true PH26712A (en) | 1992-09-15 |
Family
ID=11182925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH37251A PH26712A (en) | 1987-07-30 | 1988-07-21 | Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5010056A (ko) |
| EP (1) | EP0301392B1 (ko) |
| JP (1) | JPS6450823A (ko) |
| KR (1) | KR890001584A (ko) |
| AT (1) | ATE76753T1 (ko) |
| AU (1) | AU618547B2 (ko) |
| DK (1) | DK393188A (ko) |
| IT (1) | IT1222395B (ko) |
| NO (1) | NO883200L (ko) |
| NZ (1) | NZ225546A (ko) |
| PH (1) | PH26712A (ko) |
| ZA (1) | ZA885417B (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0383931A (ja) * | 1989-08-29 | 1991-04-09 | Sumitomo Pharmaceut Co Ltd | 低刺激性ｇｒｆ経鼻投与製剤 |
| ES2067624T3 (es) * | 1989-11-16 | 1995-04-01 | Ph & T S R L | Un procedimiento de preparacion de una composicion farmaceutica liquida para administracion nasal. |
| US5502067A (en) * | 1994-02-04 | 1996-03-26 | Morgan; Julia A. | Treating apneahypopnea/snoring in humans |
| US5500205A (en) * | 1994-02-23 | 1996-03-19 | Enviro Pac International, L.I.C. | Lachrymator aerosol formulations |
| US5861431A (en) * | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| AUPN801296A0 (en) | 1996-02-12 | 1996-03-07 | Csl Limited | Stabilised growth hormone formulation and method of preparation thereof |
| AU733047C (en) | 1997-02-24 | 2002-05-16 | S.L.A. Pharma Ag | Pharmaceutical composition |
| US8048875B1 (en) | 1997-02-24 | 2011-11-01 | S.L.A. Pharma Ag | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| CA2366922C (en) * | 1999-04-21 | 2008-07-22 | 1355540 Ontario Inc. | Formulations for detecting asthma |
| EP1189596A1 (de) * | 1999-06-02 | 2002-03-27 | Norbert Dr.med. Klöcker | Pharmazeutische zusammensetzung zur nasalen anwendung von wasserlöslichen wirkstoffen |
| CA2325106A1 (en) * | 1999-12-06 | 2001-06-06 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
| JP3498041B2 (ja) * | 2000-05-29 | 2004-02-16 | 科研製薬株式会社 | プラルモレリン含有点鼻用製剤 |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| JP6556129B2 (ja) * | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドｘ受容体の阻害剤及び医薬としての使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU565912B2 (en) * | 1982-12-10 | 1987-10-01 | Syntex (U.S.A.) Inc. | Lhrh antagronist preparations for intra-nasal administration |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| IT1169873B (it) * | 1983-10-21 | 1987-06-03 | Prodotti Formenti Srl | Composizione farmaceutica ad attivita' sistemica anticolinesterasica, agonista-colinergica ed antimuscarinica |
| US4818531A (en) * | 1985-02-06 | 1989-04-04 | Eli Lilly And Company | Growth hormone and thyroid hormone |
| JPS62126135A (ja) * | 1985-11-25 | 1987-06-08 | Sumitomo Pharmaceut Co Ltd | 経鼻投与用ｇｒｆ製剤 |
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US4880778A (en) * | 1986-05-12 | 1989-11-14 | Eastman Kodak Company | Combinations having synergistic growth hormone releasing activity and methods for use thereof |
-
1987
- 1987-07-30 IT IT21513/87A patent/IT1222395B/it active
-
1988
- 1988-07-14 DK DK393188A patent/DK393188A/da not_active Application Discontinuation
- 1988-07-19 NO NO88883200A patent/NO883200L/no unknown
- 1988-07-20 EP EP88111657A patent/EP0301392B1/en not_active Expired - Lifetime
- 1988-07-20 AT AT88111657T patent/ATE76753T1/de active
- 1988-07-21 PH PH37251A patent/PH26712A/en unknown
- 1988-07-25 NZ NZ225546A patent/NZ225546A/en unknown
- 1988-07-25 US US07/223,378 patent/US5010056A/en not_active Expired - Fee Related
- 1988-07-25 ZA ZA885417A patent/ZA885417B/xx unknown
- 1988-07-26 AU AU20051/88A patent/AU618547B2/en not_active Ceased
- 1988-07-27 KR KR1019880009436A patent/KR890001584A/ko not_active Application Discontinuation
- 1988-07-28 JP JP63187052A patent/JPS6450823A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU618547B2 (en) | 1992-01-02 |
| ATE76753T1 (de) | 1992-06-15 |
| ZA885417B (en) | 1989-06-28 |
| DK393188A (da) | 1989-01-31 |
| IT8721513A0 (it) | 1987-07-30 |
| NZ225546A (en) | 1990-12-21 |
| EP0301392B1 (en) | 1992-06-03 |
| DK393188D0 (da) | 1988-07-14 |
| IT1222395B (it) | 1990-09-05 |
| EP0301392A1 (en) | 1989-02-01 |
| AU2005188A (en) | 1989-02-02 |
| NO883200D0 (no) | 1988-07-19 |
| JPS6450823A (en) | 1989-02-27 |
| KR890001584A (ko) | 1989-03-27 |
| NO883200L (no) | 1989-01-31 |
| US5010056A (en) | 1991-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH26712A (en) | Pharmaceutical composition for intranasal administration comprising GH-releasing hormone a cholinergic agonist and optionally a bile salt | |
| CA1288048C (en) | Aqueous steroid formulations for nasal administration | |
| EP0498069B1 (en) | New use of peptide derivative | |
| KR101546596B1 (ko) | 베포타스틴 조성물 | |
| US8859531B2 (en) | Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration | |
| AU2010287421B2 (en) | Therapeutic agent for rhinitis | |
| HU227519B1 (en) | Synergic pharmaceutical composition containing combination of formoterol and budesonide | |
| BG106946A (bg) | Използване на антагонисти на централни канабиноидни рецептори за получаване на лекарствени средстваза улесняване спирането на консумацията на тютюн | |
| US4983595A (en) | Aqueous steroid formulations for nasal administration | |
| SA97180522B1 (ar) | مثبطات الترجيع reflux | |
| US6369115B1 (en) | Stabilized powder formulations | |
| CA2277365A1 (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 | |
| US6521266B1 (en) | Composition for growth hormone production and release, appetite suppression, and methods related thereto | |
| EP1225878B1 (en) | Rar-gamma selective retinoid agonists for the treatment of emphysema | |
| Derelanko et al. | Carbenoxolone sodium protects rat gastric mucosa against ethanol-induced necrosis | |
| JP2003505419A (ja) | ケトチフェンを含む眼用組成物 | |
| EP0843998B1 (en) | Oral pharmaceutical composition having antipyretic, analgesic and antiinflammatory activity | |
| CA1223210A (en) | Antisnoring agent | |
| IL148691A (en) | Pharmaceutical preparations containing cyclosonide | |
| JPH04210648A (ja) | コルチコステロイド治療組成物 | |
| AU637773B2 (en) | Fruity flavoured nasal decongestant composition | |
| US20020114832A1 (en) | Pharmaceutical preparation comprising peppermint oil and caraway oil in delayed release form | |
| HU194736B (en) | Improved process for production of antiinflammable preparative | |
| JP2891738B2 (ja) | アルコール吸収抑制剤 | |
| JP3665616B2 (ja) | ローヤルゼリー製剤 |